$CPRX
Catalyst Pharmaceuticals Inc

2019 Q4 Form 10-Q Financial Statement

#000119312519290006 Filed on November 12, 2019

View on sec.gov

Income Statement

Concept 2019 Q4 2019 Q3 2019 Q2
Revenue $30.12M $30.90M $28.84M
YoY Change 5924.51%
Cost Of Revenue $4.400M $4.387M $4.262M
YoY Change
Gross Profit $25.72M $26.51M $24.58M
YoY Change
Gross Profit Margin 85.38% 85.8% 85.22%
Selling, General & Admin $11.41M $8.068M $8.988M
YoY Change 64.65% 121.39% 241.6%
% of Gross Profit 44.36% 30.43% 36.57%
Research & Development $6.310M $4.597M $4.629M
YoY Change -25.06% 1.29% 24.96%
% of Gross Profit 24.53% 17.34% 18.84%
Depreciation & Amortization $20.00K $6.532K $10.00K
YoY Change 100.0% -29.72% 22.31%
% of Gross Profit 0.08% 0.02% 0.04%
Operating Expenses $17.72M $12.66M $17.88M
YoY Change 15.51% 54.78% 182.18%
Operating Profit $8.007M $13.85M $10.96M
YoY Change -153.94% -269.2% -272.97%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $400.0K $393.4K $450.4K
YoY Change 17.65% 14.45% 21.5%
Pretax Income $8.410M $14.24M $11.41M
YoY Change -158.0% -281.64% -291.27%
Income Tax $480.0K $608.4K $449.7K
% Of Pretax Income 5.71% 4.27% 3.94%
Net Earnings $7.930M $13.63M $10.96M
YoY Change -154.69% -273.88% -283.73%
Net Earnings / Revenue 26.32% 44.11% 38.01%
Basic Earnings Per Share $0.08 $0.13 $0.11
Diluted Earnings Per Share $0.07 $0.13 $0.10
COMMON SHARES
Basic Shares Outstanding 103.0M 103.0M 102.9M
Diluted Shares Outstanding 107.0M 105.9M

Balance Sheet

Concept 2019 Q4 2019 Q3 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.50M $76.50M $59.90M
YoY Change 76.64% 23.99% -12.43%
Cash & Equivalents $89.51M $44.98M $23.42M
Short-Term Investments $5.000M $31.60M $36.50M
Other Short-Term Assets $4.300M $3.300M $1.500M
YoY Change 152.94% 312.5% 114.29%
Inventory $1.957M $599.8K $269.9K
Prepaid Expenses
Receivables $10.54M $10.10M $10.38M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $111.4M $90.58M $72.06M
YoY Change 101.79% 44.97% 4.3%
LONG-TERM ASSETS
Property, Plant & Equipment $210.5K $141.1K $147.6K
YoY Change -14.24% -29.84% -21.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $5.000M $5.000M
YoY Change -100.0% 0.0% 0.0%
Other Assets $0.00 $0.00 $0.00
YoY Change
Total Long-Term Assets $1.013M $6.111M $6.178M
YoY Change -80.76% 16.87% 18.79%
TOTAL ASSETS
Total Short-Term Assets $111.4M $90.58M $72.06M
Total Long-Term Assets $1.013M $6.111M $6.178M
Total Assets $112.4M $96.69M $78.23M
YoY Change 85.9% 42.8% 5.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.117M $4.147M $3.329M
YoY Change 76.16% 209.25% 260.8%
Accrued Expenses $19.98M $13.84M $10.82M
YoY Change 178.52% 550.32% 401.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $24.10M $17.98M $14.15M
YoY Change 153.37% 418.46% 359.16%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change 200.0% 250.0% 700.0%
Total Long-Term Liabilities $600.0K $700.0K $800.0K
YoY Change 200.0% 250.0% 700.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.10M $17.98M $14.15M
Total Long-Term Liabilities $600.0K $700.0K $800.0K
Total Liabilities $24.75M $18.71M $14.95M
YoY Change 156.01% 414.92% 363.6%
SHAREHOLDERS EQUITY
Retained Earnings -$128.7M -$136.6M -$150.2M
YoY Change -19.85% -6.47% 8.7%
Common Stock $103.4K $103.0K $102.9K
YoY Change 0.64% 0.34% 0.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.63M $77.98M $63.28M
YoY Change
Total Liabilities & Shareholders Equity $112.4M $96.69M $78.23M
YoY Change 85.9% 42.8% 5.31%

Cashflow Statement

Concept 2019 Q4 2019 Q3 2019 Q2
OPERATING ACTIVITIES
Net Income $7.930M $13.63M $10.96M
YoY Change -154.69% -273.88% -283.73%
Depreciation, Depletion And Amortization $20.00K $6.532K $10.00K
YoY Change 100.0% -29.72% 22.31%
Cash From Operating Activities $12.29M $16.26M $14.02M
YoY Change -255.57% -333.62% -394.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$10.00K
YoY Change -100.0% -100.0% 0.0%
Acquisitions
YoY Change
Other Investing Activities $31.65M $5.050M -$9.860M
YoY Change 130.01% -33.55% 99.6%
Cash From Investing Activities $31.65M $5.050M -$9.880M
YoY Change 131.02% -33.29% 99.6%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 580.0K 260.0K 190.0K
YoY Change 286.67% 160.0% 1800.0%
NET CHANGE
Cash From Operating Activities 12.29M 16.26M 14.02M
Cash From Investing Activities 31.65M 5.050M -9.880M
Cash From Financing Activities 580.0K 260.0K 190.0K
Net Change In Cash 44.52M 21.57M 4.330M
YoY Change 648.24% 2938.03% -144.64%
FREE CASH FLOW
Cash From Operating Activities $12.29M $16.26M $14.02M
Capital Expenditures $0.00 $0.00 -$10.00K
Free Cash Flow $12.29M $16.26M $14.03M
YoY Change -256.56% -334.63% -395.37%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q3 us-gaap Short Term Investments
ShortTermInvestments
31561673
CY2019Q3 us-gaap Long Term Investments
LongTermInvestments
5008800
CY2018Q4 us-gaap Long Term Investments
LongTermInvestments
5008243
CY2019Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2018Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
8888
CY2019Q3 us-gaap Assets
Assets
96690559
CY2018Q4 us-gaap Assets
Assets
60449962
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
44983218
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16559400
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
36922213
CY2019Q3 us-gaap Inventory Net
InventoryNet
599801
CY2018Q4 us-gaap Inventory Net
InventoryNet
56012
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3339399
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1649781
CY2019Q3 us-gaap Assets Current
AssetsCurrent
90579443
CY2018Q4 us-gaap Assets Current
AssetsCurrent
55187406
CY2019Q3 us-gaap Liabilities
Liabilities
18708021
CY2018Q4 us-gaap Liabilities
Liabilities
9666153
CY2018Q4 us-gaap Other Accrued Liabilities Noncurrent
OtherAccruedLiabilitiesNoncurrent
154799
CY2019Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4147029
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2337367
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
17982321
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
96690559
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60449962
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
103041
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
102739
CY2019Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
214478406
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
211265279
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19428
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20248
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9511354
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-136618337
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-160563961
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
13845152
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8182603
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
393415
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
343730
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
608388
us-gaap Operating Income Loss
OperatingIncomeLoss
23816572
us-gaap Operating Income Loss
OperatingIncomeLoss
-20451898
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1187091
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
947993
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1058039
us-gaap Net Income Loss
NetIncomeLoss
23945624
us-gaap Net Income Loss
NetIncomeLoss
-19503905
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
14238567
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7838873
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
25003663
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19503905
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4597039
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4538369
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8067792
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3644234
CY2019Q3 cprx Total Operating Expenses
TotalOperatingExpenses
17052292
CY2018Q3 cprx Total Operating Expenses
TotalOperatingExpenses
8182603
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12534362
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11502235
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35193
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
34725401
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
36790854
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5565824
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2330
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-9450
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13627849
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7848323
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29226047
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
537962
CY2019Q3 cprx Available For Sale Securities Due Within One Year Fair Value
AvailableForSaleSecuritiesDueWithinOneYearFairValue
19965700
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
25471974
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8949663
cprx Total Operating Expenses
TotalOperatingExpenses
48367210
cprx Total Operating Expenses
TotalOperatingExpenses
20451898
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39676
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-45948
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
23985300
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19549853
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
50783809
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
103041033
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
103041033
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
102739257
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
102739257
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
933411
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
924996
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
89350
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
192550
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
817060
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
13560
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-644503
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
28446
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
10959948
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
51175627
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
63281567
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
256062
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2330
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
13630179
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
77982538
us-gaap Profit Loss
ProfitLoss
23945624
us-gaap Profit Loss
ProfitLoss
-19503905
us-gaap Depreciation
Depreciation
26718
us-gaap Depreciation
Depreciation
25485
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
543789
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1689618
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-356924
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1809662
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-604591
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6400279
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-185812
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
19370
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
146064
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
39676
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-45948
CY2018Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.79
CY2018Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.64
CY2018 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
20248
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
15389107
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
4.64
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-11-30
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
7600000
CY2019Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
19965700
CY2019Q3 cprx Prepaid Research Fee
PrepaidResearchFee
372784
CY2018Q4 cprx Prepaid Research Fee
PrepaidResearchFee
358209
CY2019Q3 us-gaap Prepaid Insurance
PrepaidInsurance
151474
CY2018Q4 us-gaap Prepaid Insurance
PrepaidInsurance
800261
CY2019Q3 cprx Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
112356
CY2018Q4 cprx Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
17030
CY2019Q3 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
537587
CY2018Q4 cprx Prepaid Subscription Fees
PrepaidSubscriptionFees
170552
CY2019Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
430838
CY2018Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
303729
CY2019Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
281645
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
442572
CY2019Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
140557
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
197147
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
141088
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
245425
CY2019Q3 us-gaap Depreciation
Depreciation
6532
CY2018Q3 us-gaap Depreciation
Depreciation
9294
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1739719
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1941449
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
531174
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
66436
CY2019Q3 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
725700
CY2018Q4 cprx Other Noncurrent Accrued Expenses And Other Liabilities
OtherNoncurrentAccruedExpensesAndOtherLiabilities
154799
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1232567
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1311061
CY2019Q3 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
768114
CY2018Q4 cprx Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
821633
CY2019Q3 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
6880265
CY2018Q4 cprx Accrued License Fees Current
AccruedLicenseFeesCurrent
3000000
CY2019Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
14560992
CY2018Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
7328786
CY2019Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13835292
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7173987
us-gaap Share Based Compensation
ShareBasedCompensation
2675467
us-gaap Share Based Compensation
ShareBasedCompensation
2521023
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
817060
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
758176
CY2019Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2018Q3 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
19428
cprx Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
three months
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.79
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
40310595
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
33408
CY2018Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
154799
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4448
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
10095352
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
952340
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
725700
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30897444
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4387461
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
72183782
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
10360874
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.13
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.13
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.19
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102974105
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102641504
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102864571
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
102598740
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
107045234
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102641504
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105821609
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
102598740
cprx Non Cash Change In Right Of Use Asset
NonCashChangeInRightOfUseAsset
181301
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10095352
cprx Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
204724
CY2019Q3 us-gaap Trading Securities Realized Gain Loss
TradingSecuritiesRealizedGainLoss
0
us-gaap Trading Securities Realized Gain Loss
TradingSecuritiesRealizedGainLoss
4980
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
4071129
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2957038
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8100000
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
74079
us-gaap Operating Lease Cost
OperatingLeaseCost
222237
us-gaap Operating Lease Payments
OperatingLeasePayments
245663
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
15915
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1020133
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0481
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
84061
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
339605
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
349788
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
329662
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1103116
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
82983
CY2019Q3 cprx Lessee Operating Lease Liability Payments Total
LesseeOperatingLeaseLiabilityPaymentsTotal
1020133
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
294433
CY2019Q3 cprx Accrued Variable Consideration
AccruedVariableConsideration
1330981
CY2019Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1058039
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.0418
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.000
us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.21
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2019-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001369568
dei Entity Registrant Name
EntityRegistrantName
CATALYST PHARMACEUTICALS, INC.
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Shell Company
EntityShellCompany
false
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Trading Symbol
TradingSymbol
CPRX
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Security12b Title
Security12bTitle
Common Stock
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
us-gaap:ProductMember
CY2019Q3 cprx Prepaid Manufacturing Expense
PrepaidManufacturingExpense
1734360
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
us-gaap Lessor Operating Lease Option To Extend
LessorOperatingLeaseOptionToExtend
1 year
us-gaap Lessor Operating Lease Option To Terminate
LessorOperatingLeaseOptionToTerminate
1 year
CY2019Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q4 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8100000
CY2018Q3 cprx Trading Securities Sales
TradingSecuritiesSales
0
cprx Trading Securities Sales
TradingSecuritiesSales
0
CY2019Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
103047033
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
80963812
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
971340
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33032
CY2018Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-21826
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-5699892
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
76246466
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10549
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
776510
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8500
CY2018Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-14672
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-5965140
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
71062213
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
758176
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104532
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-9450
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7838873
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
64076598
us-gaap Nature Of Operations
NatureOfOperations
<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:4%;"><div style="font-weight:bold;display:inline;">1.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organization and Description of Business. </div></div></div></td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px;"></div><div style="clear: both; max-height: 0px; background: none;"></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Catalyst Pharmaceuticals, Inc. and subsidiary (collectively, the Company) is a biopharmaceutical company focused on developing and commercializing innovating therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Anti-MuSK antibody positive myasthenia gravis (MuSK-MG), Congenital Myasthenic Syndromes (CMS), and Spinal Muscular Atrophy (SMA) Type 3. </div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On November&#160;28, 2018, the U.S. Food and Drug Administration, or FDA, granted approval of Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> for the treatment of adults with LEMS. On January&#160;15, 2019, the Company launched its first product, Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>, in the United States for the treatment of adults with LEMS (age 17 and above). </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets, raising capital, and selling its product. The Company incurred operating losses in each period from inception through March&#160;31, 2019, and started reporting operating income in the three and six month periods ended June 30, 2019. The Company has been able to fund its cash needs to date through several public and private offerings of its securities and from revenues from its product sales. See Note 12. </div></div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Capital Resources </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">While there can be no assurance, based on currently available information, the Company estimates that it has sufficient resources to support its operations for at least the next 12 months from the issuance date of this Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-Q.</div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company may raise required funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company&#8217;s current stockholders. There can be no assurance that any required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company&#8217;s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company&#8217;s business. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:4%;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:5%;"><div style="font-weight:bold;display:inline;">c.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">USE OF ESTIMATES. </div>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. </div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:4%;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:5%;"><div style="font-weight:bold;display:inline;">m.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CONCENTRATION OF RISK. </div>The Company sells its product in the United States through an exclusive distributor to specialty pharmacies. Therefore, its distributor and specialty pharmacies account for all of its trade receivables and net product revenues. The creditworthiness of its Customer is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for doubtful accounts primarily based on the credit worthiness of its Customer, historical payment patterns, aging of receivable balances and general economic conditions. </div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company currently has a single product with limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of the lead product, Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>, and expects Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> to constitute virtually all of product revenue for the foreseeable future. The Company&#8217;s success depends on its ability to effectively commercialize Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>. </div></div><div style="font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company relies exclusively on third parties to formulate and manufacture Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> and its drug candidates. The commercialization of Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div> and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company does not intend to establish its own manufacturing facilities. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of Firdapse<div style="font-size: 7.4pt; vertical-align: top;;vertical-align: super;font-size: smaller;display:inline;">&#174;</div>. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs. </div></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt; background: none;"><table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;times new roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px; table-layout: fixed;;width:100%;"><tr style="page-break-inside: avoid;"><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;width:4%;">&#160;</td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;;width:5%;"><div style="font-weight:bold;display:inline;">s.</div></td><td style="padding-left: 0px; padding-top: 0px; padding-bottom: 0px;;text-align:left;;vertical-align:top;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">RECLASSIFICATIONS.</div> Certain prior year amounts in the consolidated financial statements have been reclassified to conform to the current year presentation. </div></div></td></tr></table></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
28423818
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-46880389
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57496702
cprx Change In Accrued Interest And Accretion Of Discount On Investments
ChangeInAccruedInterestAndAccretionOfDiscountOnInvestments
185536
cprx Change In Accrued Interest And Accretion Of Discount On Investments
ChangeInAccruedInterestAndAccretionOfDiscountOnInvestments
405082
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
22320032
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17795958
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
19946272
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15409355
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
537962
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
141616
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10616313

Files In Submission

Name View Source Status
0001193125-19-290006-index-headers.html Edgar Link pending
0001193125-19-290006-index.html Edgar Link pending
0001193125-19-290006.txt Edgar Link pending
0001193125-19-290006-xbrl.zip Edgar Link pending
cprx-20190930.xml Edgar Link completed
cprx-20190930.xsd Edgar Link pending
cprx-20190930_cal.xml Edgar Link unprocessable
cprx-20190930_def.xml Edgar Link unprocessable
cprx-20190930_lab.xml Edgar Link unprocessable
cprx-20190930_pre.xml Edgar Link unprocessable
d786857d10q.htm Edgar Link pending
d786857dex311.htm Edgar Link pending
d786857dex312.htm Edgar Link pending
d786857dex321.htm Edgar Link pending
d786857dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending